Intervju med vd Andreas Bhagwani gällande den pågående företrädesemissionen
Intervju från 1 oktober 2024 med vd Andreas Bhagwani gällande den pågående emissionen.
Intervju från 1 oktober 2024 med vd Andreas Bhagwani gällande den pågående emissionen.
Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a customer in China. The order is the second order placed by this customer and the value of the new order amounts to approximately SEK 3.7 million. The customer is a pharmaceutical manufacturer that in June this year placed a first order for NLAB Saga® for production, after a period of evaluation of the product. Today’s order is thus the second
Den 29 augusti offentliggjorde Nanologica att bolaget avser att genomföra en fullt garanterad företrädesemission av units om ca 99,4 MSEK. I intervjun berättar vd Andreas Bhagwani mer om emissionen och bakgrunden till den.
FINANCIAL SUMMARY Net sales for the second quarter amounted to SEK 2,174 thousand (672) and for the half-year to SEK 7,211 thousand (1,026) Operating loss for the quarter amounted to SEK -9,832 thousand (-13,312) and for the half-year to SEK -25,163 thousand (-24,032) Loss before tax for the quarter amounted to SEK -11,126 thousand (-14,671) and for the half-year to SEK -27,860 thousand (-26,764) Earnings per share before and after dilution were SEK -0.25 (-0.41)
Nanologica has received an order for the company’s silica-based purification media NLAB Saga® from a customer in China who has previously evaluated the product. The value amounts to approximately SEK 2 million. The customer is a pharmaceutical manufacturer that has evaluated NLAB Saga® on a small scale and has now placed an order for production. “In China, we see a very strong activity in the GLP-1 analogue segment as a result of the patent for